Preprint Short Note Version 2 Preserved in Portico This version is not peer-reviewed

Future Considerations for the mRNA–Lipid Nanoparticle Vaccine Platform

Version 1 : Received: 17 December 2020 / Approved: 21 December 2020 / Online: 21 December 2020 (10:26:54 CET)
Version 2 : Received: 23 December 2020 / Approved: 24 December 2020 / Online: 24 December 2020 (13:51:51 CET)

A peer-reviewed article of this Preprint also exists.

Journal reference: Current Opinion in Virology 2021
DOI: 10.1016/j.coviro.2021.03.008


Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccine candidates against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology.

Subject Areas

mRNA-LNP vaccines; side effects; dendritic cells

Comments (1)

Comment 1
Received: 24 December 2020
Commenter: Botond Igyártó
Commenter's Conflict of Interests: Author
Comment: Reworded the PEG-related section and included extra references. The acknowledgment section was also updated.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.